Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
AAM Urges FDA To Reassess Nitrosamines
Generics Industry Body Proposes Science-Driven, Risk-Based Approach
Oct 14 2020
•
By
Akriti Seth
The generics industry proposes proactive actions to FDA to mitigate nitrosamine-related challenges • Source: Shutterstock
More from Generics
More from Products